Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker — Stella

Home/Brain Cancer/

View on ClinicalTrials.gov

Recruiting

Back to Brain Cancer trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Sally B Mansur, Lebanon, New Hampshire

Key details

Phase

Safety & dosing

Sponsor

David W. Roberts

Collaborators

National Institute of Neurological Disorders and Stroke (NINDS), Carl Zeiss Meditec, Inc.

Enrollment target

~30 participants

Started

March 2016

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

21 Years and older

Last updated August 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.